



Review Article

## The reality of managing asthma in sub-Saharan Africa – Priorities and strategies for improving care

Kevin Mortimer<sup>1</sup>, Refiloe Masekela<sup>2</sup>, Obianuju B Ozoh<sup>3</sup>, Eric Donn Bateman<sup>4</sup>, Rebecca Nantanda<sup>5</sup>, Arzu A. Yorgancıoğlu<sup>6</sup>, Jeremiah Chakaya<sup>7</sup>, Helen K. Reddel<sup>8</sup>

<sup>1</sup>Department of Medicine, University of Cambridge, Cambridge, United Kingdom, <sup>2</sup>Department of Pediatrics, University of Kwazulu Natal, Durban, South Africa, <sup>3</sup>Department of Medicine, University of Lagos/Lagos University Teaching Hospital, Lagos, Nigeria, <sup>4</sup>Department of Medicine, Division of Pulmonology, University of Cape Town, Cape Town, South Africa, <sup>5</sup>Makerere University Lung Institute, Kampala, Uganda, <sup>6</sup>Department of Pulmonology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, <sup>7</sup>Department of Medicine, Kenyatta University, Teaching Hospital, Nairobi, Kenya, <sup>8</sup>The Woolcock Institute of Medical Research, The University of Sydney, Sydney, Australia.

**\*Corresponding author:**

Refiloe Masekela,  
Department of Pediatrics,  
University of Kwazulu Natal,  
Durban, South Africa.

[masekelar@ukzn.ac.za](mailto:masekelar@ukzn.ac.za)

Received : 06 September 2022

Accepted : 21 September 2022

Published : 04 October 2022

**DOI**

10.25259/JPATS\_37\_2022

**Quick Response Code:**



### ABSTRACT

Asthma is the most common non-communicable disease in children and remains one of the most common throughout the life course. The great majority of the burden of this disease is seen in low-income and middle-income countries (LMICs), which have disproportionately high asthma-related mortality relative to asthma prevalence. This is particularly true for many countries in sub-Saharan Africa. Although inhaled asthma treatments (particularly those containing inhaled corticosteroids) markedly reduce asthma morbidity and mortality, a substantial proportion of the children, adolescents, and adults with asthma in LMICs do not get to benefit from these, due to poor availability and affordability. In this review, we consider the reality faced by clinicians managing asthma in the primary and secondary care in sub-Saharan Africa and suggest how we might go about making diagnosis and treatment decisions in a range of resource-constrained scenarios. We also provide recommendations for research and policy, to help bridge the gap between current practice in sub-Saharan Africa and Global Initiative for Asthma (GINA) recommended diagnostic processes and treatment for children, adolescents, and adults with asthma.

**Keywords:** Asthma, Low-middle-income country, Asthma guideline, Global initiative for asthma, Asthma medication

### INTRODUCTION

Asthma is the most common non-communicable disease in children and remains one of the most common throughout the life course. The multi-country Global Asthma Network (GAN) Phase I study recently reported that around one in 10 children and one in 15 adults have symptoms of asthma, with a high burden of severe symptoms (approximately 50% of children and adolescents and 40% of adults).<sup>[1-3]</sup> The Global Burden of Disease study estimated that there were 21.6 million disability-adjusted life years and 461,069 deaths attributable to asthma globally in 2019.<sup>[4,5]</sup>

The great majority of the burden of this disease is seen in low-income and middle-income countries (LMICs). The World Bank<sup>[6]</sup> subdivides middle-income countries into lower-middle income and upper-middle income; the lower-middle-income countries, in particular, have shown an increase in the prevalence of asthma symptoms over time and have a disproportionately high asthma-related mortality relative to asthma prevalence.<sup>[1,7,8]</sup>

Most countries in sub-Saharan Africa (SSA) are categorized by the World Bank as low income or lower-middle income.<sup>[6]</sup> Health systems in these countries are generally weak, unprepared

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

©2022 Published by Scientific Scholar on behalf of Journal of the Pan African Thoracic Society

to respond to the needs of people with non-communicable diseases, are designed primarily to respond to acute care needs, and are restrained by limited access to effective and affordable asthma care often even the most basic care. There are many challenges in addressing the rising burden of non-communicable diseases, including chronic respiratory diseases like asthma. The global alliance against chronic respiratory diseases (GARDs) has reported that very few patients in low-income and lower-middle-income countries receive adequate diagnostic investigations and treatment for chronic respiratory diseases.<sup>[9]</sup> In addition to poor access to asthma medicines and diagnostic technologies and the high out-of-pocket expenditure associated with asthma care, there is still limited integration of asthma care into primary care, which is the first point of contact with health care for over 60% of patients.<sup>[10,11]</sup> Accordingly, children, adolescents, and adults with asthma living in SSA are at a particularly high risk of avoidable morbidity and mortality due to asthma.

There is also the challenge of inadequate human resource capacity to manage asthma. In some SSA countries, the few available health workers have reported low competency in managing patients with chronic respiratory diseases.<sup>[12,13]</sup> While some progress has been made toward understanding how to integrate non-communicable diseases such as diabetes mellitus and hypertension into primary care, important gaps exist for chronic respiratory diseases such as asthma.<sup>[13]</sup>

In this review, we discuss the diagnosis and treatment of asthma in children, adolescents, and adults in SSA. We review the literature describing how asthma is diagnosed and treated in SSA and place current practice within the context of African national, regional, and selected international recommendations for asthma diagnosis and treatment from the World Health Organization (WHO), the International Union Against Tuberculosis (TB) and Lung Disease (The Union), and the Global Initiative for Asthma (GINA). We consider the reality faced by clinicians managing asthma in the primary and secondary care settings in SSA and suggest how we might go about making diagnosis and treatment decisions in a range of resource-constrained scenarios. We also provide recommendations for research and policy, to help bridge the gap between current practice in SSA and GINA recommended diagnostic processes and treatment for children, adolescents, and adults with asthma.

## HEALTH SYSTEM FACTORS AFFECTING ASTHMA MANAGEMENT IN SSA

### Asthma strategies and guidelines in SSA

A national asthma strategy (or national asthma program) is a set of actions agreed upon and enacted by governments to systematically improve asthma outcomes across the population. A comprehensive national asthma strategy

requires political commitment at the national government level (including policies, legislation, and funding for capacity building) and can involve the creation of a registry for outcome data, asthma management guidelines, economic analysis and process evaluation, and provision of universal health coverage with essential asthma medicines and support of asthma research.<sup>[14,15]</sup>

A cross-sectional survey of GAN centers was conducted in 2013–2015 to ascertain which countries have a national asthma strategy.<sup>[14]</sup> Of the 18 African countries surveyed, only Sudan and Malawi reported having an asthma strategy.<sup>[14]</sup> GAN also maintains an updated list of national guidelines<sup>[16]</sup> and documented these in the Global Asthma Report 2014<sup>[17]</sup> [Table 1].

There are no regional asthma guidelines for SSA. However, guidelines developed for LMICs by the WHO,<sup>[18]</sup> the Union<sup>[19]</sup> and Medicines Sans Frontières<sup>[20]</sup> [Table 2] are relevant in this region and are being used by some SSA countries with context-specific local adaptations.<sup>[16]</sup> The WHO also publishes a regularly updated Model List of Essential Medicines,<sup>[21]</sup> which includes one or more asthma medicines from each of the following classes: Short-acting beta<sub>2</sub> agonists (SABAs), inhaled corticosteroids (ICSs), ICS plus long-acting beta<sub>2</sub>-agonist (LABA) combinations, short-acting muscarinic antagonists, and long-acting muscarinic antagonists.

Some SSA countries adopt the GINA strategy report to guide asthma diagnosis and management. GINA was launched in 1993 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and WHO.<sup>[22]</sup> The GINA report<sup>[23]</sup> is an annually updated global strategy for asthma, underpinned by an ongoing process of reviewing published evidence on asthma management and prevention.<sup>[24]</sup> This evidence-based strategy can be adapted for local health systems and medicine availability, recognizing the need for asthma care to be tailored to the circumstances of individual countries. However, at present, the recommended GINA approaches to diagnosis and asthma medication [Figures 1-3] cannot be implemented in countries with the most severe resource limitations.

## CURRENT STATUS OF ASTHMA DIAGNOSIS IN SSA

Asthma is a clinical diagnosis made by recognizing typical patterns of respiratory symptoms and supported by evidence of variable expiratory airflow limitation.<sup>[23]</sup>

### Underdiagnosis of asthma

Asthma is commonly underdiagnosed in SSA. In a recently reported cross-sectional survey of 519 adults with chronic respiratory symptoms not explained by TB, attending

**Table 1:** National asthma guidelines and strategies in sub-Saharan Africa.

World Bank income group	Country	National asthma guideline	National asthma strategy	
Low	Burkina Faso	?	No	
	Burundi	?	?	
	Central African Republic	?	?	
	Chad	?	?	
	Congo, Democratic Republic	?	?	
	Eritrea	?	?	
	Ethiopia	Yes	?	
	The Gambia	Yes	No	
			International guidelines adopted in addition: WHO-PEN	
	Guinea	?	?	
	Guinea-Bissau	?	?	
	Liberia	?	?	
	Madagascar	?	?	
	Malawi	Yes	Yes	
	Mali	No	No	
			International guideline adopted: WHO-PEN	
	Mozambique	?	?	
	Niger	?	?	
	Rwanda	?	?	
	Sierra Leone	?	No	
	Somalia	?	?	
	South Sudan	?	?	
	Sudan	?	Yes (adults)	
	Togo	?	?	
	Uganda	No	No	
			International guideline adopted: GINA	
	Lower middle	Angola	?	?
Benin		No	No	
			International guidelines adopted: WHO-PEN, The Union	
Cabo Verde		?	?	
Cameroon		No	No	
			International guideline adopted: GINA	
Comoros		?	?	
Congo, Republic		?	?	
Cote D'Ivoire		?	?	
Eswatini		?	?	
Ghana		No	No	
			International guideline adopted: WHO-PEN	
Kenya		Yes	No	
			International guideline adopted in addition: WHO	
Lesotho		?	?	
Mauritania		?	?	
Nigeria		Yes	No	
Sao Tome and Principe		?	?	
Senegal	No	No		
		International guideline adopted: GINA		
Tanzania	?	?		

(Contd...)

**Table 1:** (Continued).

World Bank income group	Country	National asthma guideline	National asthma strategy
Upper middle	Zambia	No International guideline adopted: GINA	No
	Zimbabwe	No	No
	Botswana	?	?
	Equatorial Guinea	?	?
	Gabon	?	?
	Mauritius	?	?
	Namibia	No	?
High	South Africa	Yes	No
	Seychelles	?	?

?: Unknown status (existence of a national guideline or strategy not verified by Global Asthma Network), GINA: Global Initiative for Asthma strategy report, WHO-PEN: World Health Organization Package of Essential Noncommunicable Disease Interventions for Primary Care,<sup>[18]</sup> The Union: International Union Against Tuberculosis and Lung Disease guidelines.<sup>[19]</sup> World Bank income classifications 2021–2022.<sup>[6]</sup> Global Asthma Network surveys and reports<sup>[14,16,17]</sup>

hospital clinics in Kenya, Ethiopia, and Sudan, asthma was the diagnosis made in 34% of cases, but a history of wheeze in the past 12 months was reported by 71%.<sup>[25]</sup> This discrepancy suggests substantial underdiagnosis. In Nigeria, it has been estimated that <50% of people with asthma receive the diagnosis, with children in rural regions at high risk of underdiagnosis.<sup>[26]</sup> People with chronic respiratory symptoms in SSA often seek help from widely available TB services, but such assessment typically concludes with a diagnosis of “not TB” with few receiving an alternative diagnosis or treatment.<sup>[27]</sup>

#### Limited access to diagnostic tests

International guidelines recommend the use of spirometry to demonstrate variable expiratory airflow limitation to support the diagnosis of asthma, if possible, before starting treatment.<sup>[23,28]</sup> However, in many SSA healthcare facilities, spirometry is absent or not consistently available. Furthermore, where payment is required, may be unaffordable for patients and caregivers. On the other hand, facilities and staff often lack training on how to perform and interpret spirometry accurately.<sup>[29-33]</sup> In Nigeria, doctors have also reported a lack of access to diagnostic facilities as a major barrier to good asthma practice.<sup>[33]</sup> In Uganda, spirometry testing is reported to be largely unaffordable, costing the lowest paid government worker a month's salary (a frequently used benchmark metric for affordability).<sup>[30]</sup>

The use of peak expiratory flow (PEF) meters is proposed in some guidelines as an alternative and usually less costly method for demonstrating variable expiratory airflow limitation.<sup>[18,23,28,34]</sup> However, even so, they are not available in many countries in SSA. A study of health system preparedness for managing chronic lung diseases in Sudan and Tanzania identified the lack of access to PEF meters for diagnostic purposes as an important barrier to care.<sup>[35]</sup>

#### Psychosocial factors contributing to underdiagnosis of asthma

It is also important to recognize that a diagnosis of asthma may not be welcomed by patients and parents of children with asthma, especially where myths and stigma surround the diagnosis.<sup>[36]</sup> Such obstacles present substantial barriers to effective long-term treatment. For example, in Kenya, studies of children and adults with asthma report reluctance to admit to or accept this diagnosis, even within families.<sup>[37]</sup>

#### PRAGMATIC APPROACHES TO THE DIAGNOSIS OF ASTHMA IN RESOURCE-CONSTRAINED SSA SETTINGS

[Table 3] shows three scenarios representing diagnostic options commonly found in resource-constrained SSA settings and suggests a pragmatic approach to asthma diagnosis in each of these scenarios.

Where it is not possible to record any objective measurement of airflow limitation, the diagnosis of asthma is based entirely on clinical assessment in which history forms a major part. This pragmatic syndromic approach comes at the cost of precision. However, the benefits of making a diagnosis based only on history and physical examination likely outweigh the risks in SSA, where the major issues are under-recognition, underdiagnosis, and undertreatment. This is especially so in countries where a diagnosis may open the door to safe and effective inhaled therapies.

#### PEF meters

When clinical history supports the diagnosis of asthma, but spirometry is not available, the PEF measurement can be used to confirm variable expiratory airflow limitation,

**Table 2:** Asthma treatment levels recommended in guidelines developed for low-resource settings.

Guideline	WHO-PEN	MSF	Union
Medication recommendations	<p>Step 1: As-needed inhaled salbutamol</p> <p>Step 2: Regular low-dose inhaled beclometasone (starting dose: adults 100 mcg twice daily; children 100 mcg once or twice daily) plus as-needed inhaled salbutamol</p> <p>Step 3: Regular medium-dose inhaled beclometasone (adults: 200 mcg or 400 mcg twice daily) plus as-needed salbutamol</p> <p>Step 4: Add low-dose oral theophylline</p> <p>Step 5: Add low-dose oral prednisolone (e.g., &lt;10 mg)</p>	<p>Intermittent asthma: As-needed inhaled salbutamol</p> <p>Mild persistent asthma: Regular inhaled beclometasone* plus as-needed inhaled salbutamol</p> <p>Moderate persistent asthma (symptoms daily): Regular inhaled beclometasone* plus inhaled salbutamol 4 times daily</p> <p>Severe persistent asthma: Regular inhaled beclometasone* plus inhaled salbutamol 4–6 times daily</p>	<p>Intermittent asthma: As-needed inhaled salbutamol</p> <p>Mild: HFA beclometasone 100 mcg, 2 puffs/day plus as-needed inhaled salbutamol</p> <p>Moderate: HFA beclometasone 100 mcg, 4 puffs/day plus as-needed inhaled salbutamol</p> <p>Severe: HFA beclometasone 100 mcg, 8 puffs/day plus as-needed inhaled salbutamol</p>
Strengths	<p>Emphasis on inhaled ICS</p> <p>Practical guidance for management with limited resources</p>		
Limitations	<p>Risk of adverse effects with theophylline at step 4</p> <p>Risk of addition of regular oral prednisolone before other approaches considered</p>	<p>Risks associated with beta<sub>2</sub> receptor downregulation with frequent salbutamol dosing in patients with moderate or severe persistent asthma</p>	
		<p>Risk of withholding ICS from patients with intermittent asthma who may benefit</p>	
	<p>Risk of over-reliance on salbutamol</p> <p>Risk of non-adherence to ICS resulting in salbutamol-only treatment</p> <p>ICS-formoterol (or other ICS-LABA combination) is not considered a treatment option at any step</p> <p>Lack of specific pediatric management guidelines</p>		

ICS: Inhaled corticosteroid; GINA: Global Initiative for Asthma; Union: International Union Against Tuberculosis and Lung Disease; MSF: Médecins Sans Frontières; WHO-PEN: World Health Organization Package of Essential Noncommunicable Disease Interventions for Primary Care. \*MSF states that doses depend on asthma severity: Children 50–100 mcg twice daily; increase to 200 mcg twice daily if necessary (up to maximum 800 mcg daily). Adults 100–250 mcg twice daily, increase to 500 mcg twice daily if necessary (up to maximum 1500 mcg daily). World Health Organization,<sup>[18]</sup> Médecins Sans Frontières,<sup>[20]</sup> International Union Against Tuberculosis and Lung Disease<sup>[19]</sup>

either as a rapid response to bronchodilator or as within-day variability measured over 2 weeks.

Guidance on using PEF in diagnosis is provided in the GINA strategy report,<sup>[23]</sup> the WHO Package of Essential Non-communicable Disease Interventions for Primary Care (WHO-PEN),<sup>[18]</sup> and the European Respiratory Society (ERS) guidelines for the diagnosis of asthma in adults<sup>[34]</sup> and in children 5–16 years.<sup>[28]</sup> Training in the use of PEF meters is relatively simple. Such tests should preferably be completed before starting long-term controller treatment.

Based on a Grading of Recommendations, Assessment, Development, and Evaluation analysis, ERS guidelines advise that PEF may be considered in the diagnosis of asthma if no other lung function test is available. However, they suggest that PEF variability should not be considered the primary test for making a diagnosis of asthma (low-quality evidence).<sup>[28,34]</sup>

### Spirometry

In SSA countries where ready access to spirometry is not feasible, we recommend either centralized spirometry offered




**Box 6-5. Personalized management of asthma in children 5 years and younger**

**Children 5 years and younger**

**Personalized asthma management:**  
Assess, Adjust, Review response

Symptoms  
Exacerbations  
Side-effects  
Parent satisfaction



Exclude alternative diagnoses  
Symptom control & modifiable risk factors  
Comorbidities  
Inhaler technique & adherence  
Parent preferences and goals

Treat modifiable risk factors and comorbidities  
Non-pharmacological strategies  
Asthma medications  
Education & skills training

**Asthma medication options:**  
Adjust treatment up and down for individual child's needs

**PREFERRED CONTROLLER CHOICE**

Other controller options (limited indications, or less evidence for efficacy or safety)

**RELIEVER**

**CONSIDER THIS STEP FOR CHILDREN WITH:**

	STEP 1	STEP 2	STEP 3	STEP 4
		Daily low dose inhaled corticosteroid (ICS) (see table of ICS dose ranges for pre-school children)	Double 'low dose' ICS	Continue controller & refer for specialist assessment
	Consider intermittent short course ICS at onset of viral illness	Daily leukotriene receptor antagonist (LTRA), or intermittent short course of ICS at onset of respiratory illness	Low dose ICS + LTRA Consider specialist referral	Add LTRA, or increase ICS frequency, or add intermittent ICS
	As-needed short-acting beta <sub>2</sub> -agonist			
Infrequent viral wheezing and no or few interval symptoms		Symptom pattern not consistent with asthma but wheezing episodes requiring SABA occur frequently, e.g. ≥3 per year. Give diagnostic trial for 3 months. Consider specialist referral. Symptom pattern consistent with asthma, and asthma symptoms not well-controlled or ≥3 exacerbations per year.	Asthma diagnosis, and asthma not well-controlled on low dose ICS Before stepping up, check for alternative diagnosis, check inhaler skills, review adherence and exposures	Asthma not well-controlled on double ICS

GINA 2022, Box 6-5

© Global Initiative for Asthma, www.ginasthma.org

**Figure 1:** GINA 2022 personalized asthma management for children 5 years and younger. ICS: Inhaled corticosteroids, LTRA: Leukotriene receptor antagonist, SABA: Short-acting beta<sub>2</sub> agonist. Source: Boxes 6–5, GINA strategy 2022.<sup>[23]</sup>

in secondary or tertiary care centers where patients may be referred for spirometry or promoting the use of PEF meters in the primary and secondary care levels.

Where spirometry is available, it should be used as part of the diagnostic workup, as per the guidance in the GINA strategy report (2022).<sup>[23]</sup> It is important to note that in patients with long-standing asthma, especially those with a history of severe exacerbations, airflow limitation may become persistent (i.e., with less likelihood of demonstrating a significant bronchodilator response).

**CURRENT STATUS OF ASTHMA TREATMENT IN SSA**

Like underdiagnosis, undertreatment of asthma is a global problem and particularly common in SSA. A study done in Nigeria found that only 11% of people with asthma used an ICS, and asthma symptoms were controlled in only 6.2%.<sup>[38]</sup> The burden of asthma was high in this study, with three-quarters of respondents reporting absenteeism from school or work due to asthma in the preceding year.<sup>[38]</sup> Furthermore, a prospective cohort study in Uganda reported that only 33% of participants with asthma had controlled asthma, of which 33% were on inhaled controller medications, and 60% had one or more asthma exacerbations each year.<sup>[39]</sup> A hospital-


based study in Uganda found that, in children aged <5 years with asthma symptoms, over 90% were rather diagnosed with pneumonia and treated with antibiotics, thus missing opportunities to address the correct chronic disease.<sup>[40]</sup>

In Kenya, only about 60% of people with asthma diagnosis had received asthma medications, and these were usually limited to oral salbutamol or oral prednisolone, with inhaled treatment only deemed necessary for those with the most severe disease.<sup>[41]</sup> In some countries, including Kenya, there is a preference for oral medications over inhaled medications and fear of ICS.<sup>[37]</sup> An audit-based study in South Africa found that only 31.5% of children with asthma had well-controlled asthma and 17.6% had been admitted to hospital in the previous year.<sup>[42]</sup>

Lack of access (availability and affordability) to purpose-designed spacers or pediatric doses of asthma medicines is also a challenge for clinicians managing asthma in LMICs.<sup>[43]</sup>

**PRAGMATIC APPROACHES TO THE TREATMENT OF ASTHMA IN RESOURCE-CONSTRAINED SSA SETTINGS**

[Table 3] includes scenarios for medical treatment options commonly encountered in resource-constrained SSA settings



**Figure 2:** GINA 2022 personalized asthma management for children 6–11 years. BUD-FORM: Budesonide-formoterol, ICS: Inhaled corticosteroid, LABA: Long-acting beta<sub>2</sub> agonist, LTRA: Leukotriene receptor antagonist, MART: Maintenance and reliever therapy with ICS-formoterol, OCS: Oral corticosteroid, SABA: Short-acting beta<sub>2</sub> agonist. Source: Box 3-5B, GINA strategy 2022.<sup>[23]</sup> For initial asthma treatment in children aged 6–11 years, Boxes 3-4C and 3-4D in GINA strategy 2022. For low, medium, and high ICS doses in children, Boxes 3-6 in GINA strategy 2022.

and makes pragmatic suggestions on how to approach asthma management within these constraints.

### All patients

We suggest that all patients, regardless of what asthma medicines are available, should receive asthma education and an action plan (written or pictorial) including advice about when to seek emergency treatment. This should be tailored to the individual patient's circumstances and the health services they might access in the event of an exacerbation. Patients receiving any inhaled medications should be taught how to use the inhaler, and the technique should be checked at each visit to a healthcare center. Individual asthma education for self-management or parental management can be delivered by doctors, trained allied health professionals such as nurses, or trained lay health workers.<sup>[44,45]</sup>

### Oral salbutamol, theophylline, and prednisolone

Oral salbutamol, theophylline, and prednisolone are widely available and affordable. In some countries, these are the only available medicines for the maintenance

treatment of asthma and emergency management of asthma exacerbations. This limited range of treatment options is common in SSA and represents the lowest quality of asthma care as it is associated with a high risk of serious side effects. GINA does not recommend the use of oral salbutamol or theophylline where inhaled therapy is available.<sup>[23]</sup> While acknowledging that clinicians in some contexts are constrained to work with this restricted formulary, all involved in health care in SSA are urged to work toward the phasing out these asthma treatments and their replacement with inhaled therapies both for relief and as maintenance treatment, on the basis that these are both safer and considerably more effective.


For patients living in remote areas, it is particularly important that action plans make provision for potentially life-saving management in the event of a severe asthma attack. This may include an emergency supply of oral prednisolone (a single dose or short course) to be taken according to written instructions when symptoms worsen. It is important to note that an inhaled SABA kept at home for emergencies (even if unaffordable for day-to-day use) together with a short course of oral prednisolone may be lifesaving.



Box 3-5A. Personalized management for adults and adolescents to control symptoms and minimize future risk

### Adults & adolescents 12+ years

**Personalized asthma management**  
Assess, Adjust, Review  
for individual patient needs



#### CONTROLLER and PREFERRED RELIEVER

(Track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever

#### STEPS 1 – 2

As-needed low dose ICS-formoterol

#### STEP 3

Low dose maintenance ICS-formoterol

#### STEP 4

Medium dose maintenance ICS-formoterol

#### STEP 5

Add-on LAMA  
Refer for assessment of phenotype. Consider high dose maintenance ICS-formoterol, ± anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP

RELIEVER: As-needed low-dose ICS-formoterol

See GINA severe asthma guide

#### CONTROLLER and ALTERNATIVE RELIEVER

(Track 2). Before considering a regimen with SABA reliever, check if the patient is likely to be adherent with daily controller

#### STEP 1

Take ICS whenever SABA taken

#### STEP 2

Low dose maintenance ICS

#### STEP 3

Low dose maintenance ICS-LABA

#### STEP 4

Medium/high dose maintenance ICS-LABA

#### STEP 5

Add-on LAMA  
Refer for assessment of phenotype. Consider high dose maintenance ICS-LABA, ± anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP

RELIEVER: As-needed short-acting beta<sub>2</sub>-agonist

Other controller options for either track (limited indications, or less evidence for efficacy or safety)

Low dose ICS whenever SABA taken, or daily LTRA, or add HDM SLIT

Medium dose ICS, or add LTRA, or add HDM SLIT

Add LAMA or LTRA or HDM SLIT, or switch to high dose ICS

Add azithromycin (adults) or LTRA. As last resort consider adding low dose OCS but consider side-effects

GINA 2022, Box 3-5A

© Global Initiative for Asthma, www.ginasthma.org

**Figure 3:** GINA 2022 personalized asthma management for adults and adolescents. HDM: House dust mite, ICS: Inhaled corticosteroid, LABA: Long-acting beta<sub>2</sub>-agonist, LAMA: Long-acting muscarinic antagonist, LTRA: Leukotriene receptor antagonist, OCS: oral corticosteroid, SABA: Short-acting beta<sub>2</sub> agonist, SLIT: Sublingual immunotherapy. Source: Box 3-5A in GINA strategy 2022.<sup>[23]</sup> For recommendations about initial asthma treatment in adults and adolescents, Boxes 3-4A and 3-4B in GINA strategy 2022. For low, medium, and high ICS doses for adults and adolescents, Boxes 3-6 in GINA strategy 2022.

In some regions, daily or alternate-day oral prednisolone is the only option for controlling symptoms and limiting exacerbations. However, clinicians and patients need to acknowledge and be alert to the high risk of adverse effects of long-term use of this treatment.<sup>[46]</sup>

### Inhaled SABA

Inhaled SABA (usually salbutamol) offers a considerable advantage over oral bronchodilators both in terms of effectiveness and safety, and used as needed should be preferred to oral bronchodilators. As with all inhaled therapies, it is important that careful attention is given to ensuring that the patient can use the inhaler effectively. A spacer device that may improve delivery can be made at little cost from disposable plastic drink bottles and this has been noted to be as equally effective.<sup>[47]</sup> The use of SABA alone to manage asthma is intended only for settings in which ICS cannot be obtained. On grounds of safety, GINA recommends against the use of as-needed SABA without the concurrent use of an ICS, since the addition of a reliever combined or taken concurrently with an ICS is associated with a large reduction in severe exacerbations and potentially asthma mortality.<sup>[23]</sup>

### ICS and ICS-formoterol

Where ICS is available, it is important that this is offered to all patients with asthma, in line with GINA 2022 recommendations and based on evidence that it substantially reduces asthma mortality and morbidity.<sup>[23]</sup>

Where appropriate ICS-formoterol combinations are available and affordable, we recommend using ICS-formoterol according to GINA 2022 “Track 1” for adolescents/adults.<sup>[23]</sup> Formoterol is a rapid-onset LABA. While several ICS-LABA combinations have been developed, ICS-formoterol, used either as-needed only (for patients with mild asthma) or as both maintenance and reliever therapy (“MART”), is the preferred option for managing asthma of all severities, based on published evidence.<sup>[23]</sup> The budesonide-formoterol combination can be used as needed for symptom relief in either of these regimens, with safety and efficacy demonstrated for formoterol up to a total daily dose (maintenance plus as-needed doses) of 72 mcg (54 mcg delivered dose).

There is now a large body of evidence, primarily from high-income countries, supporting the use of MART



**Table 3: Pragmatic approaches to diagnosis and treatment of asthma in resource-constrained settings.\***

Diagnosis of asthma	
Pragmatic approach	Notes
<b>Scenario 1. No diagnostic technologies are currently available</b>	
<p>Clinical diagnosis based on:</p> <ol style="list-style-type: none"> <li>1. Recognizing typical symptoms (cough, wheeze, and dyspnea) that fluctuate over time and increase with exposure to triggers (e.g., respiratory infections, allergens, exercise, cold air, or air pollution)</li> <li>2. Recognizing symptoms that raise the suspicion of alternative diagnoses, particularly TB and HIV-AIDS (e.g., fever, weight loss, malaise, and chronic sputum production)</li> <li>3. Considering factors that increase the probability that the respiratory symptoms are caused by asthma (e.g., history of childhood eczema, family history of allergies and/or asthma, and &gt;3 episodes/year requiring health-care visits)</li> <li>4. Observing short-term (minutes) resolution of symptoms in response to an inhaled bronchodilator (e.g., salbutamol) and/or long-term control of symptoms with a treatment trial of ICS-containing therapy.</li> </ol>	<p>If no improvement with recommended asthma treatment, or if symptoms are not typical of asthma, assess for alternative diagnoses or refer to a higher level of care.</p> <p>In children aged ≤5 years, differential diagnosis is broad, including viral infections presenting with asthma-like symptoms. The probability of asthma is highest in those:</p> <ul style="list-style-type: none"> <li>• Presenting with &gt;3 episodes of wheezing per year</li> <li>• With symptoms that persist &gt;10 days after an acute respiratory tract infection</li> <li>• Who remain symptomatic between flare-ups</li> <li>• With a personal or family history of atopy.</li> </ul> <p>Where there are no diagnostics clinicians should advocate for access to peak flow meters (primary care level) and spirometers (secondary/tertiary care level)</p>
<b>Scenario 2. PEF but not spirometry is currently available</b>	
<p>Method 1. Bronchodilator response: Measure PEF before and 15 min after giving 2 puffs (200 mcg) of salbutamol. Improvement in PEF ≥20% increases likelihood of a diagnosis of asthma (compared with COPD and other diagnoses).<sup>[18]</sup></p> <p>Method 2. PEF variability:<sup>[34]</sup> Monitor over 2 weeks. Variation of &gt;20% in adults or &gt;12% in children supports asthma diagnosis.</p> <p>Method 3. Therapeutic trial:<sup>[23]</sup> Document symptoms and PEF. Treat with regular ICS and as-needed SABA for 4 weeks (with a 1-week course of oral corticosteroids if necessary). PEF improvement &gt;20% from baseline supports diagnosis of asthma.</p>	<p>These tests should be completed before starting long-term controller treatment.</p> <p>Interpret lack of significant bronchodilator response with caution; most patients with asthma show &lt;20% increase in PEF after salbutamol.<sup>[18]</sup></p> <p>PEF variability over 2 weeks can confirm the diagnosis of asthma or identify the need for further investigation.</p> <p>The absence of variable expiratory flow measured by PEF does not rule out the diagnosis of asthma.<sup>[23,34]</sup></p> <p>Guidance available in:</p> <ul style="list-style-type: none"> <li>• GINA strategy report<sup>[23]</sup></li> <li>• WHO-PEN<sup>[18]</sup></li> <li>• ERS guidelines<sup>[28,34]</sup></li> </ul>
<b>Scenario 3. Spirometry available</b>	
<p>Make diagnosis based on history of variable respiratory symptoms, confirmed expiratory airflow limitation and confirmed variability in lung function:</p> <ol style="list-style-type: none"> <li>1. Identify expiratory airflow limitation: reduced FEV<sub>1</sub> (&lt;LLN or &lt;80% predicted) and FEV<sub>1</sub>/FVC &lt;LLN or &lt;0.8</li> <li>2. Identify excessive variability in expiratory airflow: Measure FEV<sub>1</sub> before and 10–15 minutes after inhalation of 400 mcg salbutamol. In adults, adolescents, and children with variable respiratory symptoms, FEV<sub>1</sub> increases by ≥12% and ≥200 mL confirms the diagnosis of asthma.</li> </ol>	<p>Other methods include measuring FEV<sub>1</sub>:<sup>[23]</sup></p> <ul style="list-style-type: none"> <li>• Before and after a therapeutic trial</li> <li>• Before and after challenge tests</li> <li>• Between visits over time.</li> </ul> <p>Guidance (including other methods) is available in GINA strategy report.<sup>[23]</sup></p> <p>Bronchodilator response &lt;12% does not exclude asthma.</p>
<b>Treatment of asthma</b>	
<i>All settings</i>	
Provide all patients with asthma education and an asthma action plan (written or pictorial). Clinicians should advocate for access to affordable inhaled asthma medications for children, adolescents, and adults and skills training for health professionals and lay workers.	
<b>Scenario 1. Only oral salbutamol, theophylline, and prednisolone are currently available**</b>	
<p>Acute care pragmatic approaches:</p> <ol style="list-style-type: none"> <li>1. Provide oral prednisolone (course or single dose) for emergency use, with instructions on asthma action plan.</li> <li>2. Use oral SABA and theophylline with caution and for as short a duration as possible given their narrow therapeutic ranges to manage symptoms</li> </ol> <p>Maintenance treatment pragmatic approaches:</p> <ol style="list-style-type: none"> <li>1. Oral salbutamol to control symptoms if no inhaled bronchodilator is available. Titrate to individual lowest beneficial dose to minimize adverse effects.</li> </ol>	<p>These approaches are not best practices but represent a necessary compromise where inhaled SABA and ICS are not available.</p> <p>The best and safest approach is to reserve oral prednisolone for the treatment of exacerbations and avoid regular use. However, maintenance of oral prednisolone might be necessary if it is the only option for controlling symptoms and limiting exacerbations.</p>

(Contd...)

**Table 3:** (Continued).

Pragmatic approach	Notes
2. Low dose of prednisolone daily or every alternate day if necessary to control symptoms and limit exacerbations. 3. Oral theophylline if it is the only bronchodilator treatment option available. If blood level monitoring is not possible, the safest option may be to avoid exceeding the lowest age-appropriate dose. Titrate to individual lowest beneficial dose to minimize adverse effects.	Frequent or long-term prednisolone is associated with adverse effects – monitor and discuss with patient or caregiver. Maintenance of prednisolone is rarely warranted in children. Oral salbutamol and oral theophylline have systemic adverse effects and do not address underlying airway inflammation, so patient remains at risk of exacerbations and asthma death. Salbutamol is preferable to theophylline if inhaled bronchodilator therapy is not available. Theophylline has a narrow therapeutic window. Ideally, blood levels should be monitored, but this approach is extremely unlikely to be available in resource-limited settings. Concurrent use of theophylline and salbutamol is unlikely to achieve sufficient additional benefit to offset adverse effects.
<b>Scenario 2. Inhaled SABA available** but not ICS</b>	
Provide training in correct inhaler technique. If inadequate symptom control, a trial of daily oral theophylline, taken in addition to as-needed inhaled salbutamol, is preferable to resort to regular prednisolone. If inhaled SABA can be obtained but is unaffordable for day-to-day use, provide one inhaler for emergencies and usage instructions (with oral prednisolone) in asthma action plan.	Train patient in correct inhaler technique. Use spacer with pMDI (can be made from plastic drink bottle). In patients using as-needed SABA, oral salbutamol or oral theophylline are generally unlikely to provide additional benefit. The GINA recommendation against the use of as-needed SABA without ICS is based on the very large reduction in severe exacerbations and asthma mortality seen with ICS-containing treatment, compared with SABA-only treatment. <sup>[23]</sup>
<b>Scenario 3. ICS but not ICS-formoterol available**</b>	
Train patient in correct inhaler technique. Where ICS (but not ICS-formoterol) is available and affordable, use ICS according to GINA 2022 “Track 2” for adolescents/adults, to avoid SABA-only treatment: <sup>[23]</sup> <ul style="list-style-type: none"> <li>• For patients who do not need maintenance ICS treatment, instruct patients to take a dose of ICS each time they use SABA for symptom relief.</li> <li>• For patients who need maintenance treatment, use ICS regularly, with SABA taken as needed for symptom relief.</li> </ul>	In patients prescribed maintenance ICS, use strategies to encourage adherence.
<b>Scenario 4. ICS-formoterol is available*</b>	
Train patient in correct inhaler technique Recommended treatment options: <ul style="list-style-type: none"> <li>• As-needed-only low dose ICS-formoterol for patients with mild asthma</li> <li>• MART with low-dose ICS-formoterol as both maintenance and reliever treatment for patients with moderate asthma: patient takes regular daily dose (e.g., 1 inhalation twice daily) plus extra doses as needed for symptom relief. Double the number of maintenance inhalations for patients with severe asthma.</li> </ul>	ICS-formoterol, either as-needed only (mild asthma) or as MART is the preferred option for managing asthma of all severities, based on evidence. For budesonide-formoterol combination, safety and efficacy have been demonstrated for formoterol up to a total daily dose (maintenance plus as-needed doses) of 72 mcg (54 mcg delivered dose) on individual days.
COPD: Chronic obstructive pulmonary disease, ERS: European Respiratory Society, FEV <sub>1</sub> : Forced expiratory volume in 1 s, FEV <sub>1</sub> /FVC: Ratio of forced expiratory volume in 1 s to forced vital capacity; ICS: Inhaled corticosteroids; GINA: Global Initiative for Asthma, LLN: Lower limit of normal, MART: Maintenance and reliever therapy, PEF: Peak expiratory flow, SABA: Short-acting beta <sub>2</sub> agonists, WHO-PEN: WHO-PEN: World Health Organization Package of Essential Noncommunicable Disease Interventions for Primary Care. *Based on evidence where available and the experience of the authors. ** “Available” means both obtainable in the country and accessible/affordable	

with ICS-formoterol in adolescents and adults,<sup>[48,49]</sup> and one large study in children.<sup>[50]</sup> MART with budesonide-formoterol and beclometasone-formoterol is approved by regulators in many countries. More recently, the SYGMA 1&2,<sup>[51-53]</sup> PRACTICAL,<sup>[54]</sup> and Novel START<sup>[55]</sup> trials have

demonstrated that mild asthma in adolescents and adults can be managed effectively with just “as-needed” budesonide-formoterol ICS, with particularly large reductions in severe exacerbations and emergency visits/hospitalizations compared with inhaled SABA alone.<sup>[56]</sup> In that study, as-

needed-only low-dose budesonide-formoterol also reduced need for emergency department visits and hospitalization, compared with maintenance ICS plus as-needed SABA.<sup>[56]</sup>

In addition to its demonstrated efficacy<sup>[56]</sup> and excellent safety profile,<sup>[57,58]</sup> the use of ICS-formoterol to manage asthma across all severity levels may have special advantage for countries of SSA: Even among patients with mild asthma, the reduction in exacerbations, compared with SABA only<sup>[51-56]</sup> or maintenance ICS plus as-needed SABA,<sup>[56]</sup> would reduce the burden of acute asthma on health services. This strategy ensures that all patients receive doses of ICS. In settings where access to care is limited, even symptom prompted the use of ICS-containing medications is likely to be beneficial. The simplicity of a single inhaler for both symptom relief and (where required) maintenance treatment might make it easier for patients to use their medicines correctly. Even in well-resourced health systems, where patients have access to self-management education provided by health professionals, the historical approach that begins with SABA, along with the later addition of daily maintenance treatment, commonly confuses patients about the roles and correct use (timing and technique) of multiple inhalers. The use of a single ICS-formoterol inhaler also simplifies the process of stepping up and down between treatment levels, as it does not involve adding a second inhaler device when initiating maintenance treatment or when increasing or decreasing maintenance treatment. For some health services, this strategy may simplify drug procurement by reducing the requirement for a wider variety of products.

## APPROACHES TO STRENGTHENING HEALTH SYSTEMS FOR ASTHMA CARE IN RESOURCE-CONSTRAINED SSA COUNTRIES

### Current initiatives supporting improvement in asthma care in SSA

The WHO has a strong mandate to reduce the burden of chronic respiratory diseases in LMICs.<sup>[8]</sup> Its current (13<sup>th</sup>) General Programme of Work sets out clear frameworks for patient-centered health services to deliver care across disease types and settings.<sup>[59]</sup> The WHO considers integrated care for chronic respiratory diseases to be central to meeting these objectives. Strategies developed by the WHO to address lung health in LMICs include the Practical Approach to Lung Health (PAL)<sup>[60]</sup> and WHO-PEN<sup>[18]</sup> disease interventions to provide protocols for the diagnosis and treatment, both acute and long term, of asthma and COPD in resource-constrained settings.

GARDs focus on the needs of LMICs and vulnerable populations. It supports the WHO to establish and strengthen national policies and tailored initiatives for the prevention and control of chronic respiratory diseases.<sup>[61]</sup> GARD goals for LMICs are to improve diagnosis, acknowledging that a syndromic approach to diagnosis will

be necessary for most countries, and secure accessible and affordable treatment for all patients. The current GARD activities include demonstration projects in South Africa and Mozambique.<sup>[62,63]</sup>

GINA has made a considerable effort, particularly over recent years, to maximize the relevance of the GINA recommendations to resource-constrained settings in LMICs (and under-resourced settings within high-income countries).<sup>[23]</sup> Sections of the strategy have been expanded to address the needs of patients living in these resource-constrained settings. GINA activities include publishing articles on the implementation of the GINA strategy in the context of LMICs,<sup>[7,64-66]</sup> World Asthma Day advocacy efforts to shine a spotlight on the needs of patients with asthma around the world, including in LMICs,<sup>[67]</sup> and promoting management of asthma in LMICs as a key topic for research.<sup>[68]</sup> An important aspect of all these efforts is to ensure patients with asthma, wherever they may be and are provided with care that meets a basic quality standard as outlined in the GINA strategy.

Regional initiatives in SSA include Practical Approach to Care Kit (PACK) developed by the Knowledge Translation Unit of the University of Cape Town Lung Institute.<sup>[69-73]</sup>

### Strengthening asthma education for health professionals

Training health workers to conduct high-quality spirometry are an important priority in SSA. The Pan African Thoracic Society (PATS) has a program to provide training and education on spirometry, but there remain challenges to be overcome.<sup>[29]</sup>

In some SSA countries where ICS is available, ongoing prescribing of oral salbutamol, theophylline, and prednisolone, or sole prescription of inhaled salbutamol, may be influenced by patient preference in populations with low health literacy, or lack of access to ongoing medical education on evidence-based asthma management. A similar problem has been documented in India, where primary care physicians' lack of awareness of the importance of ICS treatment in asthma management is one of the main reasons why, even when ICS is available, many people with asthma do not use it.<sup>[66]</sup>

Therefore, we recommend that regular and updated asthma education for doctors and other health care workers be prioritized, as well as considering patient asthma education delivered by non-health professionals, especially in rural settings.

### Enabling effective asthma care delivered by non-physician health workers

The GINA report<sup>[23]</sup> cites several studies showing the effectiveness of asthma education provided by nurses, pharmacists, and lay health workers.<sup>[74-79]</sup>

Nurse-led asthma care has been shown to markedly reduce asthma exacerbations among adults in rural Cameroon.<sup>[80]</sup> Studies in Malawi have demonstrated that asthma symptoms and exacerbations can be reduced by clinical assessment, optimization of inhaled treatment, and individualized asthma education delivered by trained non-physicians,<sup>[45]</sup> and that this education is well received by parents.<sup>[44]</sup>

## RESEARCH RECOMMENDATIONS

With the notable exception of selected South African settings, research into the diagnosis and management of asthma in SSA is extremely limited.<sup>[69-73]</sup> There is only limited evidence about the implementation of the WHO-PEN asthma guidelines in SSA<sup>[81]</sup> and no clinical trial evidence from these countries on the recommended GINA approach of using ICS-formoterol as reliever (Track 1).<sup>[23]</sup> There is an urgent need to change this situation, because only relevant, locally generated evidence can inform changes to policy and increase investment into programs for the treatment of children, adolescents, and adults with asthma in SSA.

We suggest the following major priorities for asthma research in SSA:

- Baseline data – Collect and maintain accurate, regularly updated data on the prevalence of asthma, burden of symptoms, exacerbations, health system resource utilization, and the availability and affordability of the WHO essential asthma medicines and technology. These data are necessary to identify and address needs and measure progress (or lack of it) so that policy and decision makers can be held to account
- Local clinical trials – Design and conduct a clinical trial in SSA to evaluate the clinical effects and cost-effectiveness of the GINA track 1 approach (ICS-formoterol across all levels of asthma severity), compared with the current standard of care. This evidence is needed to inform changes to treatment recommendations (and investment in their implementation)
- Implementation strategies – Design and conduct implementation studies to improve access to diagnosis and acceptance of appropriate treatments. This approach might involve operationalizing the GINA recommendations in a range of health systems, with consideration of local issues including human resource capacity strengthening, medicine management and supply, and data capture systems to document effectiveness and impact on patient outcomes. We recommend strong involvement of service users (patients and caregivers) in the research process to maximize understanding of what works, why, and how
- Delivery models – Further evaluate models for delivery of asthma care within different health systems in SSA using an integrated care approach that empowers

all categories of the primary health-care personnel, including non-physicians, to diagnose and manage asthma, such as those developed for the PACK<sup>[69-73]</sup>

- Community attitudes and knowledge – Develop and evaluate innovative tools that will improve community acceptance of asthma and its management.

Substantial strengthening of research capability in SSA is needed to enable this research. It is imperative that adequate opportunities are created for this research to be led and delivered by appropriately skilled and experienced African investigators. A successful model to achieve this is the PATS Methods in Epidemiological, Clinical, and Operational Research (PATS MECOR), which offers training and networking opportunities for clinicians from SSA who are interested in research.<sup>[7,82-84]</sup>

## Policy recommendations for SSA healthcare systems

We make the following recommendations for policy and decision-makers:

- Develop national asthma strategies based on relevant evidence
- Develop evidence-based national asthma management guidelines (or adapt guidelines from elsewhere that can be implemented nationally at all levels of care)
- Develop evidence-based regional asthma management guidelines that can provide the basis for national guidelines where individual countries lack resources to develop these
- Ensure WHO essential medicines and devices for the treatment of asthma are made available and affordable to all children, adolescents, and adults
- Improve access to diagnostic tools to facilitate diagnosis of asthma in children, adolescents, and adults
- Support community-based programs that improve asthma literacy
- Reorient health systems to integrate asthma care into primary health care and improve human resource capacity through training, mentorship, and supervision programs.

## CONCLUSION

There are well-established evidence-based strategies for the management of asthma, including GINA which, if fully implemented, would have a substantial impact on the global burden of avoidable asthma morbidity and mortality. The reality of managing asthma in SSA is commonly very different: Limited by substantial resource constraints affecting access to care, diagnostics, and treatments. In this review, we have acknowledged this reality and provided some pragmatic suggestions for how to best manage children, adolescents, and adults with asthma under these resource-constrained conditions.

However, clinicians and policymakers must *not* accept these constraints as inevitable and permanent. Instead, we must develop and implement research and policy recommendations that will improve asthma care in SSA, including making WHO Essential Medicines available to all.

### Acknowledgments

We thank Jenni Harman for her editorial assistance and GINA for supporting this work.

### Declaration of patient consent

Patient's consent not required as there are no patients in this study.

### Financial support and sponsorship

Global Initiative for Asthma (GINA).

### Conflicts of interest

KM has reported advisory board fees from AstraZeneca; RM has received advisory board and honoraria and investigator initiated research from AstraZeneca and honoraria from MSD; HR reports research grants for investigator-initiated studies from AstraZeneca, GSK, and Novartis, and honoraria for participating in advisory boards or consulting for AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, and Sanofi; and for providing independent medical education at symposia funded by AstraZeneca, Boehringer Ingelheim, Chiesi, Getz, GlaxoSmithKline, Sanofi, and Teva. AAY is a member of the GINA board, EDB has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Hikma pharma, Menarini, Novartis, Orion, Regeneron, and Sanofi Genzyme, and consulting fees from AstraZeneca, Novartis, Regeneron, and Sanofi Genzyme in the past 3 years.

### REFERENCES

1. Asher MI, Rutter CE, Bissell K, Chiang CY, El Sony A, Ellwood E, *et al.* Worldwide trends in the burden of asthma symptoms in school-aged children: Global asthma network phase I cross-sectional study. *Lancet* 2021;398:1569-80.
2. Mortimer K, Lesosky M, García-Marcos L, Asher MI, Pearce N, Ellwood E, *et al.* The burden of asthma, hay fever and eczema in adults in 17 countries: GAN phase I study. *Eur Respir J* 2022;60:2102865.
3. García-Marcos L, Asher MI, Pearce N, Ellwood E, Bissell K, Chiang CY, *et al.* The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study. *Eur Respir J* 2022;60:2102866.
4. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle: Institute for Health Metrics and Evaluation (IHME); 2020. Available from: <http://ghdx.healthdata.org/gbd-results-tool> [Last accessed on 2022 Sep 06].
5. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. *Lancet* 2020;396:1204-22.
6. World Bank. World Bank Country and Lending Groups. The World Bank Group; 2021. Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> [Last accessed on 2022 Sep 06].
7. Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, *et al.* Improving lung health in low-income and middle-income countries: From challenges to solutions. *Lancet* 2021;397:928-40.
8. Meghji J, Jayasooriya S, Khoo E, Mulupi S, Mortimer K. Chronic respiratory disease in low-income and middle-income countries: From challenges to solutions. *J Pan Afr Thorac Soc* 2022;3:92-7.
9. Bousquet J, Khaltaev N, editors. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. Geneva: World Health Organization; 2007.
10. World Health Organization Regional Office for Africa. Regional Framework for Integrating Essential Noncommunicable Disease Services in Primary Health Care. Agenda Item 15, 67<sup>th</sup> Session of the Regional Committee for Africa, Victoria Falls, Republic of Zimbabwe, 28 August 1 September 2017. AFR/RC67/12 2017. Available from: <https://apps.who.int/iris/bitstream/handle/10665/334349/AFR-RC67-12-eng.pdf> [Last accessed on 2022 Sep 06].
11. Universal Health Coverage in Uganda. Looking Back and Forward to Speed up the Process. Kampala: Makerere University School of Public Health; 2018. Available from: <http://speed.musph.ac.ug/wp-content/uploads/2015/05/cover-preliminary-pages.pdf> [Last accessed on 2022 Sep 06].
12. Nantanda R, Kayingo G, Jones R, van Gemert F, Kirenga BJ. Training needs for Ugandan primary care health workers in management of respiratory diseases: A cross sectional survey. *BMC Health Serv Res* 2020;20:402.
13. Ratnayake R, Wittcoff A, Majaribu J, Nzweve JP, Katembo L, Kasonia K, *et al.* Early experiences in the integration of non-communicable diseases into emergency primary health care, Beni Region, Democratic Republic of the Congo. *Ann Glob Health* 2021;87:27.
14. Asher I, Haahtela T, Selroos O, Ellwood P, Ellwood E. Global asthma network survey suggests more national asthma strategies could reduce burden of asthma. *Allergol Immunopathol (Madr)* 2017;45:105-14.
15. Haahtela T, Klaukka T, Koskela K, Erhola M, Laitinen LA. Asthma programme in Finland: A community problem needs community solutions. *Thorax* 2001;56:806-14.
16. Global Asthma Network. Asthma Management Guidelines. Global Asthma Network; 2020. Available from: <http://globalasthmanetwork.org/management/management.php> [Last accessed on 2022 Sep 06].
17. Global Asthma Network. The Global Asthma Report 2014. Auckland, New Zealand: Global Asthma Network; 2014. Available from: [http://globalasthmareport.org/2014/global\\_](http://globalasthmareport.org/2014/global_)

- asthma\_report\_2014.pdf [Last accessed on 2022 Sep 06].
18. World Health Organization. Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-resource Settings. Geneva, Switzerland: WHO Press; 2020. Available from: [https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-\(pen\)-disease-interventions-for-primary-health-care](https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care) [Last accessed on 2022 Sep 06].
  19. Ait-Khaled N, Enarson DA, Chiang CY, Marks G, Bissell K. Management of asthma. In: A Guide to the Essentials of Good Clinical Practice. 3<sup>rd</sup> ed. Paris, France: International Union Against Tuberculosis and Lung Disease; 2008.
  20. Balkan S, Barel P, Bottineau MC, Boule P, Carreno C, Cereceda M. Médecins Sans Frontières. Clinical guidelines Diagnosis and Treatment Manual. Médecins Sans Frontières; 2021. Available from: <https://medicalguidelines.msf.org/viewport/CG/english/clinical-guidelines-16686604.html> [Last accessed on 2022 Sep 06].
  21. World Health Organization. Model List of Essential Medicines 22<sup>nd</sup> List Report. Geneva, Switzerland: World Health Organization; 2021. Available from: <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02> [Last accessed on 2022 Sep 06].
  22. Global Initiative for Asthma. About us. The Global Initiative for Asthma (GINA). GINA. Available from: <https://ginasthma.org/about-us> [Last accessed on 2022 Sep 06].
  23. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022: GINA; 2022. Available from: <https://www.ginasthma.org/reports> [Last accessed on 2022 Sep 06].
  24. Global Initiative for Asthma. Methodology. GINA; 2022. Available from: <https://ginasthma.org/about-us/methodology> [Last accessed on 2022 Sep 06].
  25. Binegdie AB, Meme H, El Sony A, Haile T, Osman R, Miheso B, *et al.* Chronic respiratory disease in adult outpatients in three African countries: A cross-sectional study. *Int J Tuberc Lung Dis* 2022;26:18-25.
  26. Oluwole O, Arinola GO, Huo D, Olopade CO. Household biomass fuel use, asthma symptoms severity, and asthma underdiagnosis in rural schoolchildren in Nigeria: A cross-sectional observational study. *BMC Pulm Med* 2017;17:3.
  27. Jayasooriya S, Dimambro-Denson F, Beecroft C, Balen J, Awokola B, Mitchell C, *et al.* Patients with presumed tuberculosis in sub-Saharan Africa that are not diagnosed with tuberculosis: A systematic review and meta-analysis. *Thorax* 2022. Doi: 10.1136/thoraxjnl-2021-217663.
  28. Gaillard EA, Kuehni CE, Turner S, Goutaki M, Holden KA, de Jong CC, *et al.* European respiratory society clinical practice guidelines for the diagnosis of asthma in children aged 5-16 years. *Eur Respir J* 2021;58:2004173.
  29. Masekela R, Zurba L, Gray D. Dealing with access to spirometry in Africa: A commentary on challenges and solutions. *Int J Environ Res Public Health* 2018;16:62.
  30. Kibirige D, Kampiire L, Atuhe D, Mwebaze R, Katagira W, Muttamba W, *et al.* Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: The Ugandan perspective. *BMC Pulm Med* 2017;17:179.
  31. Plum C, Stolbrink M, Zurba L, Bissell K, Ozoh BO, Mortimer K. Availability of diagnostic services and essential medicines for non-communicable respiratory diseases in African countries. *Int J Tuberc Lung Dis* 2021;25:120-5.
  32. Ozoh OB, Eze JN, Garba BI, Ojo OO, Okorie EM, Yiltok E, *et al.* Nationwide survey of the availability and affordability of asthma and COPD medicines in Nigeria. *Trop Med Int Health* 2021;26:54-65.
  33. Ozoh OB, Ndukwu CI, Desalu OO, Adeyeye OO, Adeniyi B. Knowledge and practice assessment, and self reported barriers to guideline based asthma management among doctors in Nigeria. *Niger J Clin Pract* 2019;22:692-700.
  34. Louis R, Satia I, Ojanguren I, Schleich F, Bonini M, Tonia T, *et al.* European respiratory society guidelines for the diagnosis of asthma in adults. *Eur Respir J* 2022; Doi: 10.1183/13993003.01585-2021.
  35. Egere U, Shayo E, Ntinginya N, Osman R, Noory B, Mpagama S, *et al.* Management of chronic lung diseases in Sudan and Tanzania: How ready are the country health systems? *BMC Health Serv Res* 2021;21:734.
  36. Zeitouni MO, Al-Moamary MS, Coussa ML, Riachy M, Mahboub B, AlHuraish F, *et al.* Challenges and recommendations for the management of asthma in the Middle East and Africa. *Ann Thorac Med* 2022;17:71-80.
  37. Simba J, Marete I, Waihenya R, Kombe Y, Mwangi A, Mburugu P, *et al.* Knowledge and perceptions on childhood asthma among care-takers of children with asthma at a national referral hospital in Western Kenya: A descriptive study. *Afr Health Sci* 2018;18:965-71.
  38. Ozoh OB, Ayuk AC, Ukwaja KN, Desalu OO, Olufemi O, Aderibigbe SA, *et al.* Asthma management and control in Nigeria: The asthma insight and reality Nigeria (AIRNIG) study. *Expert Rev Respir Med* 2019;13:917-27.
  39. Kirenga BJ, de Jong C, Mugenyi L, Katagira W, Muhofa A, Kanya MR, *et al.* Rates of asthma exacerbations and mortality and associated factors in Uganda: A 2-year prospective cohort study. *Thorax* 2018;73:983-5.
  40. Nantanda R, Tumwine JK, Ndeezee G, Ostergaard MS. Asthma and pneumonia among children less than five years with acute respiratory symptoms in Mulago Hospital, Uganda: Evidence of under-diagnosis of asthma. *PLoS One* 2013;8:e81562.
  41. Barakat D, Rockers PC, Vian T, Onyango MA, Laing RO, Wirtz VJ. Access to asthma medicines at the household level in eight counties of Kenya. *Int J Tuberc Lung Dis* 2018;22:585-90.
  42. Mash B, Rhode H, Pather M, Ainslie G, Irusen E, Bheekie A, *et al.* Quality of asthma care: Western Cape Province, South Africa. *S Afr Med J* 2009;99:892-6.
  43. Zar HJ, Levin ME. Challenges in treating pediatric asthma in developing countries. *Paediatr Drugs* 2012;14:353-9.
  44. Nkhalamba L, Rylance S, Muula AS, Mortimer K, Limbani F. Task-shifting to improve asthma education for Malawian children: a qualitative analysis. *Hum Resour Health* 2021;19:28.
  45. Rylance S, Chinoko B, Mnesa B, Jewell C, Grigg J, Mortimer K. An enhanced care package to improve asthma management in Malawian children: A randomised controlled trial. *Thorax* 2021;76:434-40.
  46. Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Jie JL, *et al.* Adverse outcomes from initiation of systemic corticosteroids for asthma: Long-term observational study. *J Asthma Allergy*

- 2018;11:193-204.
47. Zar HJ, Asmus MJ, Weinberg EG. A 500-ml plastic bottle: An effective spacer for children with asthma. *Pediatr Allergy Immunol* 2002;13:217-22.
  48. Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, *et al.* Association of inhaled corticosteroids and long-acting  $\beta$ -agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis. *JAMA* 2018;319:1485-96.
  49. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2013;4:CD007313.
  50. Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: A new strategy in pediatric asthma. *Chest* 2006;130:1733-43.
  51. Bateman ED, O'Byrne PM, FitzGerald JM, Barnes PJ, Zheng J, Lamarca R, *et al.* Positioning as-needed budesonide-formoterol for mild asthma: Effect of pre-study treatment in pooled analysis of SYGMA 1 and 2. *Ann Am Thorac Soc* 2021;18:2007-17.
  52. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, *et al.* As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. *N Engl J Med* 2018;378:1877-87.
  53. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, *et al.* Inhaled combined budesonide formoterol as needed in mild asthma. *N Engl J Med* 2018;378:1865-76.
  54. Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, *et al.* Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): A 52-week, open-label, multicentre, superiority, randomised controlled trial. *Lancet* 2019;394:919-28.
  55. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, *et al.* Controlled trial of budesonide-formoterol as needed for mild asthma. *N Engl J Med* 2019;380:2020-30.
  56. Crossingham I, Turner S, Ramakrishnan S, Fries A, Gowell M, Yasmin F, *et al.* Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. *Cochrane Database Syst Rev* 2021;5:CD013518.
  57. Jenkins CR, Bateman ED, Sears MR, O'Byrne PM. What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever? *Respirology* 2020;25:804-15.
  58. FitzGerald JM, O'Byrne PM, Bateman ED, Barnes PJ, Zheng J, Ivanov S, *et al.* Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase III SYGMA studies. *Drug Saf* 2021;44:467-78.
  59. World Health Organization. Promote Health. Keep the World Safe. Serve the Vulnerable. 13<sup>th</sup> General Programme of Work 2019-2023. Geneva: World Health Organization; 2018. Available from: <https://www.who.int/about/what-we-do/thirteenth-general-programme-of-work-2019---2023>. [Last accessed on 2022 Sep 06].
  60. Banda H, Robinson R, Thomson R, Squire SB, Mortimer K. The "practical approach to lung health" in Sub-Saharan Africa: A systematic review. *Int J Tuberc Lung Dis* 2016;20:552-29.
  61. Khaltayev N. GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership. *J Thorac Dis* 2017;9:4676-89.
  62. Bousquet J, Mohammad Y, Bedbrook A, To T, McGihon R, Bárbara C, *et al.* Country activities of global alliance against chronic respiratory diseases (GARD): Focus presentations at the 11<sup>th</sup> GARD General Meeting, Brussels. *J Thorac Dis* 2018;10:7064-72.
  63. Billo NE. Role of the global alliance against respiratory diseases in scaling up management of chronic respiratory diseases-summary meeting report. *J Thorac Dis* 2017;9:2337-8.
  64. Mortimer K, Reddel HK, Pitrez PM, Bateman ED. Asthma management in low- and middle-income countries: Case for change. *Eur Respir J* 2022;60:2103179.
  65. Masekela R, Mortimer K, Nantanda R, Lesosky M, Meme H, Devereux G, *et al.* Asthma care in Sub-Saharan Africa: Mind the gap! *J Pan Afr Thorac Soc* 2022;3:92-7.
  66. Mortimer K, Salvi S, Reddel H. Closing gaps in asthma care in India world asthma day 2022. *Indian J Med Res* 2022;154:4122.
  67. Global Initiative for Asthma. World Asthma Day 2022. GINA; 2022. Available from: <https://ginasthma.org/world-asthma-day-2022> [Last accessed on 2022 Sep 06].
  68. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, *et al.* Global initiative for asthma (GINA) Strategy 2021 executive summary and rationale for key changes. *Eur Respir J* 2021;59:2102730.
  69. Cornick R, Picken S, Wattrus C, Awotiwon A, Carkeek E, Hannington J, *et al.* The practical approach to care kit (PACK) guide: Developing a clinical decision support tool to simplify, standardise and strengthen primary healthcare delivery. *BMJ Glob Health* 2018;3 Suppl 5:e000962.
  70. Cornick R, Wattrus C, Eastman T, Ras CJ, Awotiwon A, Anderson L, *et al.* Crossing borders: the PACK experience of spreading a complex health system intervention across low-income and middle-income countries. *BMJ Glob Health* 2018;3 Suppl 5:e001088.
  71. Awotiwon A, Sword C, Eastman T, Ras CJ, Ana P, Cornick RV, *et al.* Using a mentorship model to localise the practical approach to care kit (PACK): From South Africa to Nigeria. *BMJ Glob Health* 2018;3 Suppl 5:e001079.
  72. Picken S, Hannington J, Fairall L, Doherty T, Bateman E, Richards M, *et al.* PACK child: The development of a practical guide to extend the scope of integrated primary care for children and young adolescents. *BMJ Glob Health* 2018;3:e000957.
  73. Simelane ML, Georgeu-Pepper D, Ras CJ, Anderson L, Pascoe M, Faris G, *et al.* The practical approach to care kit (PACK) training programme: Scaling up and sustaining support for health workers to improve primary care. *BMJ Glob Health* 2018;3:e001124.
  74. Armour CL, Reddel HK, LeMay KS, Saini B, Smith LD, Bosnic-Anticevich SZ, *et al.* Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: A pragmatic cluster randomized trial. *J Asthma* 2013;50:302-9.
  75. Kuethe MC, Vaessen-Verberne AA, Elbers RG, Van Aalderen WM. Nurse versus physician-led care for the management of asthma. *Cochrane Database Syst Rev* 2013;2:CD009296.

76. Klijn SL, Hiligsmann M, Evers S, Román-Rodríguez M, van der Molen T, van Boven JF. Effectiveness and success factors of educational inhaler technique interventions in asthma and COPD patients: A systematic review. *NPJ Prim Care Respir Med* 2017;27:24.
77. Federman AD, O'Connor R, Mindlis I, Hoy-Rosas J, Hauser D, Lurio J, *et al.* Effect of a self-management support intervention on asthma outcomes in older adults: The SAMBA study randomized clinical trial. *JAMA Intern Med* 2019;179:1113-21.
78. Campbell JD, Brooks M, Hosokawa P, Robinson J, Song L, Krieger J. Community health worker home visits for Medicaid-enrolled children with asthma: Effects on asthma outcomes and costs. *Am J Public Health* 2015;105:2366-72.
79. Partridge MR, Caress AL, Brown C, Hennings J, Luker K, Woodcock A, *et al.* Can lay people deliver asthma self-management education as effectively as primary care based practice nurses? *Thorax* 2008;63:778-83.
80. Kengne AP, Sobngwi E, Fezeu LL, Awah PK, Dongmo S, Mbanya JC. Nurse-led care for asthma at primary level in rural sub-Saharan Africa: The experience of Bafut in Cameroon. *J Asthma* 2008;45:437-43.
81. Chiang CY, Bissell K, Macé C, Perrin C, Marks G, Mortimer K, *et al.* The asthma drug facility and the future management of asthma. *Int J Tuberc Lung Dis* 2022;26:388-91.
82. Masekela R, Mortimer K, Aluoch J, Ozoh OB. Building research capacity to correct global health's wrongs. *Lancet Glob Health* 2022;10:e175-6.
83. Mortimer K, Nantanda R, Meghji J, Vanker A, Bush A, Ndimande N, *et al.* Africa's respiratory "big five". *J Pan Afr Thorac Soc* 2021;2:64-72.
84. Nwankwo O, Ukwaja K, Ozoh O, Akpet O, Iwara N, Nwankwo G, *et al.* The pan African thoracic society methods in epidemiologic, clinical and operations research program: A story of success told through a history of publications. *J Pan Afr Thorac Soc* 2022;3:16-24.

**How to cite this article:** Mortimer K, Masekela R, Ozoh OB, Bateman ED, Nantanda R, Yorgancioğlu AA, *et al.* The reality of managing asthma in sub-Saharan Africa – Priorities and strategies for improving care. *J Pan Afr Thorac Soc* 2022;3:105-20.